Skip to main content
Presentation
AB0780 SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, FUTURE 2. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017.
The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017)
  • P Emery
  • I McInnes
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
June, 2017
Citation Information
P Emery, I McInnes, Philip Mease and et.al.. "AB0780 SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, FUTURE 2. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017." The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017)
Available at: http://works.bepress.com/philip-mease/235/